Flagship Ventures Dives Into Microbiome, Launches Seres Health

Only a few biopharmaceutical start-ups have formed in the emerging microbiome space, but VC firm Flagship says its homegrown Seres Health, still somewhat stealthy, is developing a new category of drugs that aim to rebalance microbiome populations causing disease.

More from United States

More from North America